| Summary: | 碩士 === 國立臺灣大學 === 生物科技管理碩士在職學位學程 === 107 === Precision medicine is an indispensable part of future
medical service.This study advocated that a treatment plan in target of its tumor molecular type must be developed based on the cancer patient’s liquid biopsy to yield a better response and prognosis. It would serve as a better supplement to follow up therapies, by tracking the efficacy and tumor recurrence. The liquid biopsy does show considerable potential in the future market. In order to verify the argument,this study would explore such expectation in cancer patients who had liquid biopsy exami nation. The entire research was conducted in two phases: First, market survey with in depth clinical interview was performed to understand the product positioning of liquid biopsy for cancer patients and its possible future direction in the market.The study found: 1) The genetic sequencing of liquid biopsy for patients selected by clinical physicians could indeed help in customization of individual therapy and showed significant improvement in therapeutic outcome for some tumor cases. 2) For patients with poor tolerance to chemotherapy who might even experience some side effects, it benefited them in finding the most appropriate target drugs to minimize any adverse reactions and even maximize the chance of getting treatment as early as possible.
3) Clinical experts believed that liquid biopsy is not only suitable for some people, but its ability to analyze the patient cluster and direct marketing focus shows great potential.
|
|---|
